online pharmacy, prescription drugs online



Drugs online research references











  • Development of renal function in the transplanted patient with renal hypertension treated with enalapril
  • Effect of enalapril, furosemide and verapamil on cyclosporin concentration in whole blood
  • Cigarette smoke increases gastric ulcer size in part by an angiotensin II-mediated mechanism in rats.
  • Renin and angiotensinogen gene expression and intrarenal renin distribution during ACE inhibition.
  • Focal segmental glomerulosclerosis in adult African Americans.
  • The effect of enalapril on glomerular growth and glomerular lesions after subtotal nephrectomy in the rat: a stereological analysis.
  • Suppression of in vitro granulocytopoiesis by captopril and penicillamine.
  • Effect of enalapril on handling of a sodium chloride load by genetically hypertensive and normotensive rats.
  • Effect of enalapril on heart rate, arterial blood pressure and exocrine pancreatic secretion in the alert dog
  • Rest and exercise hemodynamic and adrenergic responses to enalapril, hydrochlorothiazide, and combination treatment in patients with systemic hypertension.
  • Mechanisms affecting the development of renal cystic disease induced by diphenylthiazole.
  • Systemic and renal hemodynamic changes after two-month treatment with enalapril in patients with essential hypertension.
  • Systemic and regional hemodynamic profile of five angiotensin I converting enzyme inhibitors in the spontaneously hypertensive rat.
  • Enhanced expression of heparin-binding EGF-like growth factor and its receptor in hypertrophied left ventricle of spontaneously hypertensive rats.
  • Thyrotropin-releasing hormone hyperactivity in the preoptic area of spontaneously hypertensive rats.
  • Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension.
  • Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems.
  • The effect of hydrochlorothiazide on the enhanced coughing associated with treatment with enalapril.
  • Long-term enalapril and hydrochlorothiazide in radiation nephritis.
  • Sublingual enalapril in hypertensive crisis. A preliminary study
  • Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
  • Serum interspecies differences in metabolic pathways of bradykinin and des-Arg9BK: influence of enalaprilat.
  • Efficacy of intrarenal ACE-inhibition estimated from the renal response to angiotensin I and II in humans.
  • Role of ANG II in hypertension produced by chronic inhibition of nitric oxide synthase in conscious rats.
  • Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass.
  • Short-term effect of angiotensin-converting enzyme inhibitor enalapril in incipient diabetic nephropathy.
  • Regression of cardiac hypertrophy in spontaneously hypertensive rats by enalapril and the expression of contractile proteins.
  • Regression of cardiac hypertrophy normalizes glucose metabolism and left ventricular function during reperfusion.
  • Comparison of the acute hypotensive effects of renin inhibition, converting enzyme inhibition, and angiotensin II antagonism in rats.
  • Enalapril in treatment of hypertension with renal artery stenosis. Changes in blood pressure, renin, angiotensin I and II, renal function, and body composition.
  • Measurement of angiotensin II concentration in rat plasma: pathophysiological applications.
  • Enalaprilat improves the impaired left ventricular pump function during exercise in hypertensives with coronary microangiopathy and with coronary artery disease.
  • Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril.
  • Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats.
  • Antihypertensive and angiotensin converting enzyme inhibitory activities of a novel dihydrobenzofuran analogue.
  • Centrally administered inhibitors of the generation and action of angiotensin II do not attenuate the increase in ACTH secretion produced by ether stress in rats.
  • Long-lasting ex vivo inhibition by perindopril of rat vascular response to angiotensin I.
  • Investigation of the inhibitory effect of N(G)-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1 receptor antagonist, GR138950.
  • Substrate- and inhibitor-specificity of a non-endothelial enzyme which forms Met5-enkephalin from Met5-enkephalin-Arg6,Phe7 in isolated rabbit ear artery: pharmacological characterization.
  • Ineffectiveness of ACE inhibitors (enalapril) on glomerular damage in rats after a 5/6 nephrectomy and a high-salt diet
  • Cilazapril and enalapril inhibit local angiotensin I conversion in human veins but lack direct venodilating properties.
  • Comparison of a new renin inhibitor and enalaprilat in renal hypertensive dogs.
  • Placental passage of angiotensin-converting enzyme inhibitors.
  • Natriuresis in conscious dogs caused by increased carotid Na+ during angiotensin II and aldosterone blockade.
  • Atrial natriuretic factor in patients with cardiac decompensation before and after chronic therapy with an angiotensin-converting enzyme inhibitor
  • Atrial natriuretic factor in patients with hypertension
  • The role of angiotensin-II in progressive diabetic glomerulopathy in the rat.
  • The role of angiotensin II in the development of hypertension and in the maintenance of glomerular filtration rate during 48 hours of renal artery stenosis in conscious dogs.
  • Protection of the arterial internal elastic lamina by inhibition of the renin-angiotensin system in the rat.
  • Ventricular remodeling: insights from pharmacologic interventions with angiotensin-converting enzyme inhibitors.
  • Attenuation of alcohol intake by a serotonin uptake inhibitor: evidence for mediation through the renin-angiotensin system.
  • The reduction in alcohol intake produced by enalapril is not attenuated by centrally administered angiotensin inhibitors.
  • Investigations into interactions between doxazosin and enalaprilat at alpha 1-adrenoceptors in anaesthetized rats.
  • Effect of dietary protein intake and angiotensin converting enzyme inhibition in Heymann nephritis.
  • Incidence of sudden cardiac death associated with coronary artery occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by chronic beta-adrenergic blockade.
  • Hemodynamic response to intravenous enalaprilat in patients with severe congestive heart failure and mitral regurgitation.
  • Placental alterations, intrauterine growth retardation and teratogenicity associated with enalapril use in pregnant rats.
  • Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats.
  • Renal effects of the acute inhibition of angiotensin-converting enzyme. I. 3) Relative roles of angiotensin II and prostanoids in early hypokalemic dysfunction
  • Renin processing studied by immunogold localization of prorenin and renin in granular juxtaglomerular cells in mice treated with enalapril.
  • Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure.
  • Prolonged converting enzyme inhibition in non-modulating hypertension.
  • Effect of converting enzyme inhibition on renin synthesis and secretion in mice.
  • Conformationally restricted inhibitors of angiotensin converting enzyme: synthesis and computations.
  • Effect of converting enzyme inhibition by enalapril on sodium homeostasis in the rat.
  • Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR.
  • Glucose tolerance test and insulin secretion in patients with essential hypertension. Effect of enalapril
  • Monitoring kidney function in patients with essential hypertension treated with enalapril
  • Attenuation of ischemia--reperfusion injury by enalapril maleat.
  • Cardiovascular effects of ketamine anesthesia in rats treated with enalapril and propranolol
  • Clinical experience with labetalol and enalapril in combination in patients with severe essential and renovascular hypertension.
  • Angioedema associated with lisinopril.
  • Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats.
  • Cardiovascular changes by long-term inhibition of the renin-angiotensin system in aging.
  • Effects of angiotensin-converting enzyme inhibition on renal dysfunction induced by moderate potassium depletion in healthy women.
  • Therapeutic, but not low-dose, angiotensin-converting enzyme inhibition causes regression of cardiovascular changes in spontaneously hypertensive rats.
  • Effects of enalapril and Dup753 on renin synthesis in mice with one hydronephrotic kidney.
  • Enalapril maleate and a lysine analogue (MK-521): disposition in man.
  • Albuminuria causes lysozymuria in rats with Heymann nephritis.
  • The effect of enalapril maleate on cerebral blood flow in chronic cerebral infarction.
  • Effects of angiotensin-converting enzyme inhibition on renal adaptations to acute furosemide administration in conscious rats.
  • Influence of the renal medulla and early treatment with enalapril upon the development of hypertension in young spontaneously hypertensive rats.
  • Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin.
  • Bradykinin-induced airway microvascular leakage is potentiated by enalaprilat but not by phosphoramidon.
  • Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction.
  • Requirement for Ca2+ mobilization and increased prostaglandin production for maximal decidualization in rats and the involvement of angiotensin II.
  • Atrial natriuretic factor modulates proximal glomerulotubular balance in anesthetized rats.
  • The incidence of cough during treatment with angiotensin converting enzyme inhibitors.
  • Antitussive effect of moguisteine on the enhanced coughing associated with enalapril in guinea-pig.
  • Effect of lisinopril monotherapy on renal hemodynamics.
  • Effects on left ventricular mass and function of low doses of enalapril for systemic hypertension.
  • Cardiac remodelling and myocardial contractility in patients with congestive heart failure treated with furosemide and enalapril.
  • Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction.
  • Recovery of erythrocyte Na(+)-K(+)-Cl- cotransport activity by enalapril.
  • Enalapril attenuates natriuresis of atrial natriuretic factor in humans.
  • Control of growth in the neonatal pig heart.
  • Effect of angiotensin-converting enzyme inhibitors on glomerular eicosanoid production in normotensive and spontaneously hypertensive rats.
  • Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor.
  • Serum concentration and effects of a single dose of enalapril maleate in patients with essential hypertension.
  • Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure.
  • Sympathetic functions in NG-nitro-L-arginine-methyl-ester-induced hypertension: modulation by the renin-angiotensin system.
  • ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption.
  • Confounding factors in non-invasive tests of neurovascular function in diabetes mellitus.
  • Angiotensin II enhances norepinephrine spillover during sympathetic activation in conscious rabbits.
  • Glomerular adaptations with normal aging and with long-term converting enzyme inhibition in rats.
  • The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors.
  • The antiproteinuric action of enalapril in stroke-prone spontaneously hypertensive rats is unrelated to alterations in urinary prostaglandins.
  • Pharmacological properties of the new non-sulfhydryl angiotensin converting enzyme inhibitor N-8-amino-1(S)-carboxyoctyl-L-alanyl-L-proline.
  • Postmarketing surveillance of enalapril. I: Results of prescription-event monitoring.
  • Hormonal and metabolic effects of enalapril treatment in hypertensive subjects with NIDDM.
  • Increased myocardial 123I-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure.
  • Cell and molecular studies of renin secretion.
  • Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-1(S)-(ethoxycarbonyl)-3-phenylpropyl-(S)-alanyl-(S)-pyroglutamic acid.
  • Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-N-(S)-1-ethoxycarbonyl-3-phenylpropyl-L-alanyl -(1S,3S,5S)-2-azabicyclo3.3.0octane-3-carboxylic acid (Hoe 498).
  • Effect of angiotensin-converting enzyme inhibition on intimal thickening in rabbit collared carotid artery.
  • Intraglomerular expression of alpha-smooth muscle actin in aging mice.
  • Simultaneous determination of enalapril maleate and hydrochlorothiazide by first-derivative ultraviolet spectrophotometry and high-performance liquid chromatography.
  • Comparison of the effects of a low protein diet and angiotensin converting enzyme inhibitors on renal insufficiency in hypertensive rats
  • Effect of enalaprilic acid on cardiac contractile response to beta-adrenergic stimulation.
  • Oxytocic effect of trypsin on the isolated rat uterus.
  • Impact of enalapril therapy on in vitro coronary artery responsiveness in pacing-induced heart failure.
  • Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats.
  • Effect of prostaglandin E2 on ion regulating and acid excretory function of the kidneys
  • Comparison of the efficacy of monotherapy with a beta-blocker, a diuretic, and ACE inhibitors in the control of blood pressure during stress
  • Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure.
  • Potentiation by enalaprilat of fenoldopam-evoked natriuresis is due to blockade of intrarenal production of angiotensin-II in rats.
  • Enalapril in the prevention of restenosis following intracoronary intervention in a swine model.
  • Effect of enalapril therapy on glomerular accumulation of immune complexes and mesangial matrix in experimental glomerulonephritis in the nonhuman primate.
  • Effect of enalapril therapy on left ventricular mass and volumes in asymptomatic chronic, severe mitral regurgitation secondary to mitral valve prolapse.
  • Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome.
  • Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent.
  • ACE inhibition in diabetic patients: effect on pressor responsiveness to noradrenaline.
  • Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension.
  • Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure.
  • Prescribing and usage patterns of two antihypertensive agents: a comparison of terazosin and enalapril.
  • Differential efficacy of perindopril and enalapril in experimental diabetic nephropathy.
  • Steady-state pharmacokinetics and pharmacodynamics of imidaprilat, an active metabolite of imidapril, a new angiotensin-converting enzyme inhibitor in spontaneously hypertensive rats.
  • Synthesis and pharmacological screening of new angiotensin converting enzyme inhibitors.
  • Hypotensive effect of a phosphorus-containing novel angiotensin converting enzyme inhibitor, (S)-1-6-amino-2hydroxy(4-phenylbutyl)phosphinyl oxy-1-oxohexyl-L-proline (SQ 29,852) in conscious hypertensive dogs.
  • Electrophysiologic effect of enalapril on guinea pig papillary muscles in vitro.
  • Anaesthesia and angiotensin-converting enzyme inhibitors. The effect of enalapril on peri-operative cardiovascular stability.
  • Primary and adaptive changes of A-type K+ currents in sympathetic neurons from hypertensive rats.
  • The pathogenetic role of endogenous angiotensin II in stress ulcer in obstructive jaundice rats.
  • Regional haemodynamic effects of captopril, enalaprilat and lisinopril in conscious water-replete and water-deprived Brattleboro rats.
  • Enalaprilat, an angiotensin-converting enzyme inhibitor, enhances functional preservation during long-term cardiac preservation. Possible involvement of bradykinin and PKC.
  • Converting enzyme inhibition and the glomerular hemodynamic response to glycine in diabetic rats.
  • Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study.
  • Rx drugs
  • An inhibitor of angiotensin converting enzyme (enalapril) augments endotoxin-induced hypotension in the pig.
  • The effect of captopril and enalapril on the cerebral circulation of normotensive rats
  • Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity.
  • Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan.
  • Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.
  • Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas.
  • Naloxone reverses the effects of enalapril and enalaprilic acid on the pressor responses to afferent vagal stimulation.
  • Differential suppression of pressure-overload cardiac and aortic hypertrophy in rats by angiotensin-converting enzyme inhibitors.
  • Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients.
  • Anomaly of the des-Arg9-bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study.
  • Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure.
  • Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats.
  • Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo.
  • Smooth muscle cell proliferation in the ductus arteriosus and the descending aorta, and effects of enalapril on SMC proliferation in perinatal rats.
  • Two inhibitors of angiotensin-converting enzyme, enalapril and captopril, increase salt appetite of rats.
  • Metabolic effects of berlipril-5 in patients with non-insulin dependent diabetes mellitus and arterial hypertension
  • Individual or combined effects of enalapril and verapamil on chronic cyclosporine nephrotoxicity in rats.
  • Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat.
  • Angiotensin converting-enzyme inhibitor treatment reduces glomerular p16INK4 and p27Kip1 expression in diabetic BBdp rats.
  • Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment.
  • Interrelationship of the kinin system, nitric oxide and eicosanoids in the antigen-induced arthritis in rabbits.
  • Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models.
  • The application of VIS spectrophotometric determination of enalapril maleate in substance, in tablets and estimation of ester group stability.
  • Differential effects of short-term ace- and AT1-receptor inhibition on postischemic injury and leukocyte adherence in vivo and in vitro.
  • Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat.
  • Rx drugs
  • Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
  • Mesenteric vasoconstriction in response to hemorrhagic shock.
  • Clinical and hemodynamic efficacy of enalapril in severe congestive heart failure
  • The influence of angiotensin-converting enzyme inhibitors on collagen content of the aorta wall in experimental hypercholesterolemia
  • Acetazolamide and enalapril combination offers complete protection from nitric oxide-deficient stroke in stroke-prone spontaneously hypertensive rats.
  • Effect of ACE inhibition on pressor, renal vascular, and adrenal responses to infusion of angiotensin I in normal subjects eating a low-salt diet.
  • Interaction between norepinephrine release and intrarenal angiotensin II formation during renal nerve stimulation in dogs.
  • Endothelin-1 attenuates bradykinin-induced hypotension in rats.
  • Effects of bunazosin hydrochloride sustained-release formulation on cerebral circulation.
  • Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes.
  • Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation.
  • Transfer of enalaprilat across rat liver cell membranes is barrier limited.
  • Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system.
  • Assessment of hemodynamic effects of angiotensin-converting enzyme inhibitor therapy in chronic aortic regurgitation by using velocity-encoded cine magnetic resonance imaging.
  • Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin.
  • Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.
  • Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats.
  • Effects of angiotensin-converting enzyme inhibitors on glucose uptake.
  • Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
  • Effect of acute intravenous ace-inhibition on the intrarenal doppler flow characteristics in hypertensive patients with and without unilateral renal artery stenosis.
  • Lipid peroxidation and activities of antioxidant enzymes in the diabetic kidney: effect of treatment with angiotensin convertase inhibitors.
  • Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
  • Effect of angiotensin II blockade on renal injury in mineralocorticoid-salt hypertension.
  • Angiotensin-converting enzyme inhibitor prevents age-related endothelial dysfunction.
  • Interactions between acute effect of angiotensin converting enzyme inhibition and salt balance on the renal function and urinary prostanoids. Studies in healthy women.
  • Different inhibition of enalaprilat and imidaprilat on bradykinin metabolizing enzymes.
  • Effect of angiotensin-converting enzyme inhibitor (enalapril or imidapril) on ventilation during exercise in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy.
  • Importance of angiogenic action of angiotensin II in the glomerular growth of maturing kidneys.
  • Regulation of liver angiotensinogen and kidney renin mRNA levels by angiotensin II.
  • Effect of chronic angiotensin II inhibition on the cardiovascular system of the normal rat.
  • Effects of converting enzyme inhibitors on renal P-450 metabolism of arachidonic acid.
  • The pancreatic islets in spontaneously hypertensive rats: islet blood flow and insulin production.
  • An attempt to assess the central action of captopril and enalaprilat.
  • Enalapril decreases angiotensin II receptors in subfornical organ of SHR.
  • Acute administration of nicotine impairs the hypotensive responses to bradykinin in rats.
  • Heart failure. A decision analytic analysis of New Zealand data using the published results of the SOLVD Treatment Trial. Studies of Left Ventricular Dysfunction.
  • Comparative effects of amlodipine (stamlo) and enalapril (enam) on arterial pressure, painless myocardial ischemia and diastolic function of left ventricle in patients with arterial hypertension
  • Abnormal renal medullary response to angiotensin II in SHR is corrected by long-term enalapril treatment.
  • Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.
  • Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy.
  • Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.
  • Determination of the antihypertensive drug cilazapril and its active metabolite cilazaprilat in pharmaceuticals and urine by solid-phase extraction and high-performance liquid chromatography with photometric detection.
  • Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors.
  • The effects of allicin and enalapril in fructose-induced hyperinsulinemic hyperlipidemic hypertensive rats.
  • Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats.
  • Weight reduction and pharmacologic treatment in obese hypertensives.
  • Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
  • Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria.
  • Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and Doppler ultrasound studies.
  • Protective role of enalapril for chronic tubulointerstitial lesions of hyperoxaluria.
  • The effect of enalapril and verapamil on the left ventricular hypertrophy and the left ventricular cardiomyocyte numerical density in rats submitted to nitric oxide inhibition.
  • Antihypertensive drugs induce structural remodeling of the penile vasculature.
  • Chronological structure of arterial pressure in hypertensive patients on enalapril
  • Late coronary artery reperfusion has additive beneficial effects on infarct expansion when combined with early angiotensin converting enzyme inhibitor therapy post myocardial infarction.
  • Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging.
  • Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme.
  • Effect of enalapril on diabetic nephropathy in OLETF rats: the role of an anti-oxidative action in its protective properties.
  • Usefulness of (123)I-BMIPP with myocardial imaging for evaluation of the efficacy of drug therapy in patients with chronic heart failure.
  • Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model.
  • Differential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats.
  • Beneficial effects of angiotensin-converting enzyme inhibitor on renal function and glucose homeostasis in diabetics with hypertension.
  • Inhibitory effect of the angiotensin converting enzyme inhibitors captopril and enalapril on the conversion of procollagen to collagen.
  • Use of enalapril, an angiotensin-converting enzyme inhibitor, in pulmonary artery hypertension
  • The role of enalapril in the prevention of ovarian hyperstimulation syndrome: a rabbit model.
  • Effects of enalapril and L-158809 on myocardial beta-adrenergic receptor density in transplanted rat hearts.
  • Splanchnic blood flow and hepatic glucose production in exercising humans: role of renin-angiotensin system.
  • Involvement of nitric oxide in the antiaggregatory effect of enalapril.
  • A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension.
  • Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice.
  • Haemodynamic effects of enalaprilat and preload in acute severe heart failure complicating myocardial infarction.
  • Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury.
  • Kallikrein-kinin system activation and its interactions with other plasma haemostatic components in the coronary artery disease.
  • Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular aldosterone.
  • Quantification of pulmonary capillary endothelium-bound angiotensin converting enzyme inhibition in man.
  • Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome.
  • Inhibitory effects of angiotensin-converting enzyme inhibitor on cefroxadine uptake by rabbit small intestinal brush border membrane vesicles.
  • Non-AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil.
  • AT(1) and AT(2) receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts.
  • Spectrophotometric and AAS determination of ramipril and enalapril through ternary complex formation.
  • Beneficial effects of angiotensin-converting enzyme inhibitors during acute revascularization.
  • The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein.
  • Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.
  • Effects of indomethacin on hemodynamic parameters after intravenous administration of propranolol and enalaprilat in rabbits.
  • Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.
  • Studies on the interactions between the angiotensin converting enzyme inhibitor enalaprilat and calcium antagonists in rats.
  • Dose-dependent inhibition of angiotensin converting enzyme by enalapril in cats.
  • Influence of captopril and enalapril on some central effects of ethanol.
  • Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration.
  • Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure.
  • B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure.
  • The metabolic effects of the angiotensin converting enzyme inhibitors in experimental diabetes mellitus
  • Effect of captopril or enalapril on renal prostaglandin E2.
  • Age-related changes in angiotensin II-stimulated proximal tubule fluid reabsorption in the spontaneously hypertensive rat.
  • Apparently high plasma angiotensin II levels in patients with essential hypertension treated by converting enzyme inhibition.
  • Enalapril and irbesartan in treatment of patients with arterial hypertension
  • Hemodynamic effects of angiotensin and renin inhibition in dogs with acute left ventricular failure.
  • Angiotensin-(1-7) and bradykinin interaction in diabetes mellitus: in vivo study.
  • Angiotensin converting enzyme inhibition decreases cell turnover in the neonatal rat heart.
  • ACE inhibitors in heart failure--switching from enalapril to perindopril.
  • Changes of endothelin in streptozotocin-induced diabetic rats: effects of an angiotensin converting enzyme inhibitor, enalapril maleate.
  • Haemodynamic effects of an angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist during hypovolaemia in the anaesthetized pig.
  • Captopril and quinapril reduce reactive oxygen species.
  • Comparative effects of enalapril, enalaprilic acid and captopril in blocking angiotensin I-induced pressor and dipsogenic responses in spontaneously hypertensive rats.
  • Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects.
  • Influence of propranolol, enalaprilat, verapamil, and caffeine on adenosine A(2A)-receptor-mediated coronary vasodilation.
  • Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats.
  • Combined effects of enalapril and spironolactone in hamsters with dilated cardiomyopathy.
  • Renal function and angiotensin AT1 receptor expression in young rats following intrauterine exposure to a maternal low-protein diet.
  • The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension.
  • Reduced activity of the kallikrein-kinin system predominates over renin-angiotensin system overactivity in all conditions of sodium balance in essential hypertensives and family-related hypertension.
  • Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin.
  • Effects of combination of cyclosporine with losartan or enalapril on kidney function in uremic rats.
  • Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril.
  • Efficacy and dosage of enalapril in congenital and acquired heart disease.
  • Role of angiotensin II in the neural control of renal function.
  • Enalaprilat improves systemic and mesenteric blood flow during resuscitation from hemorrhagic shock in dogs.
  • Effect of combined therapy with enalapril maleate and hypothiazide on the structuro-functional status of erythrocyte membranes in hypertensive patients
  • Cost reduction with project based prescription of generic ACE inhibitors
  • The effect of commonly used drugs on angiogenesis.
  • Prognostic significance of factors of membrane pathology in hypertension
  • The mechanism of protective effects of enalapril on experimental diabetic nephropathy of rats
  • Simultaneous quantitation of enalapril and enalaprilat in human plasma by 96-well solid-phase extraction and liquid chromatography/tandem mass spectrometry.
  • Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
  • Time course of vascular structural changes during and after short-term antihypertensive treatment.
  • Long-term therapy with enalapril in patients with nephrotic-range proteinuria.
  • Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat.
  • Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial.
  • Rx drugs
  • Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats.
  • Does whole body autoregulation mediate the hemodynamic responses to increased dietary salt in rats with clamped ANG II?
  • Efficacy of long-term enalapril use in combined therapy of chronic pulmonary heart
  • Effect of SQ29,852, a new angiotensin converting enzyme (ACE) inhibitor with a phosphonic acid group, on the activity of angiotensin converting enzyme from human kidney.
  • Effect of ACE inhibitors on proteinuria and renal functioning in primary glomerulopathies
  • Acute hemodynamic effects of converting enzyme inhibition in children with intracardiac shunts.
  • Acute hemodynamic effects of the active metabolite of imidapril, (4S)-3-((2S)-2-N-((1S)-1-carboxy-3-phenyl-propyl)aminopropionyl)-1- methyl-2-oxoimidazolidine-4-carboxylic acid, and enalaprilat in anesthetized dogs.
  • ACE inhibition by enalaprilate stimulates duodenal mucosal alkaline secretion via a bradykinin pathway in the rat.
  • Renal hemodynamic effects of nonhypotensive doses of angiotensin-converting enzyme inhibitors in hypertension and heart failure rats.
  • Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats.
  • Enalapril (MK-421), a new angiotensin-converting enzyme inhibitor. Acute and chronic effects in heart failure.
  • Enalapril prevents impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in diabetic rats.
  • Influence of dopamine and angiotensin II blockade on the acute response to unilateral nephrectomy in rats.
  • Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways.
  • Cell transplantation to prevent heart failure: a comparison of cell types.
  • Kidney adaptation in nitric oxide-deficient Wistar and spontaneously hypertensive rats.
  • Energy status of the rapidly paced canine myocardium in congestive heart failure.
  • Evidence for metalloprotease involvement in the in vivo effects of big endothelin 1.
  • Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function.
  • Inhibition of human platelet aggregation by endothelium-derived relaxing factor, sodium nitroprusside or iloprost is potentiated by captopril and reduced thiols.
  • The effect of ace inhibition on peripheral hemodynamics in normotensive and hypertensive patients with type II diabetes.
  • Effect of chronic enalapril treatment on prorenin, renin and sex hormones during the menstrual cycle in patients with essential hypertension
  • Control of arterial pressure and renal function during chronic renin inhibition.
  • Comparison of the effects of captopril and enalapril on oxyphenbutazone and ethanol-induced gastric lesions in rats.
  • Converting enzyme inhibition by enalapril in experimental heart failure.
  • Comparison of the actions of the angiotensin-converting enzyme inhibitors enalapril and S-9490-3 in sodium-deplete and sodium-replete spontaneously hypertensive rats.
  • Cardiac hypertrophy and salt status in chronic myocardial infarction in the rat: effects of enalapril versus salt restriction.
  • Effects of a protein load in patients with early chronic renal failure before and after angiotensin II blockade.
  • The renin-angiotensin system during pregnancy in chronically instrumented, conscious rats.
  • Interactions between enalaprilat and doxazosin at rat tail artery alpha 1-adrenoceptors.
  • Prevalence of persistent cough during long-term enalapril treatment: controlled study versus nifedipine.
  • Absorption of oral enalapril in germ-free and microbially-associated rats.
  • Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril.
  • Modulation of albuminuria by dietary protein and converting enzyme inhibition.
  • Antihypertensive effect of a renin inhibitor in marmosets with a segmental renal infarction.
  • Effects of spiraprilic acid, an angiotensin converting enzyme inhibitor, on large artery compliance in anesthetized dogs.
  • Enalapril, an inhibitor of angiotensin converting enzyme, increases the junctional conductance in isolated heart cell pairs.
  • Comparison of the effects of the dipeptidyl peptidase inhibitors captopril, ramipril, and enalapril on water intake and sodium appetite of Sprague-Dawley rats.
  • Regional cerebral blood flow during acute left ventricular failure in the dog: effect of converting enzyme inhibition.
  • Converting enzyme inhibitors (captopril, enalapril, perindopril) prevent early-post infarction ventricular fibrillation in the anaesthetized rat.
  • Effects of repeated doses of enalapril on renal function in man.
  • Pharmacokinetics of enalapril
  • Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man.
  • Effects of enalapril maleate on plasma level of inactive renin in renovascular hypertension.
  • The effect of renal function on enalapril kinetics.
  • Use of the converting enzyme inhibitor enalapril in renovascular hypertension. Effect on blood pressure, renal function, and the renin-angiotensin-aldosterone system.
  • Factors affecting renal vein renin ratio in renal artery stenosis. Secretion of inactive renin.
  • Renal effects of angiotensin converting enzyme inhibitors in hypertension.
  • Kininase II of human seminal fluid: kinetics and inhibition.
  • Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment.
  • Evidence for a vasodepressor effect of the angiotensin-converting enzyme inhibitor, MK421 (enalapril), independent of blockade of angiotensin II formation.
  • Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide.
  • Effect of captopril, enalaprilat and mercaptopropionyl glycine (MPG) on the oxidative activity of human isolated neutrophils.
  • The clinical pharmacology of enalapril.
  • Humoral and renal effects of MK-421 (enalapril) in hypertensive subjects.
  • Effects of a new angiotensin converting enzyme inhibitor, enalapril, in acute and chronic left ventricular failure in dogs.
  • Intravenous antihypertensive agents for patients unable to take oral medications.
  • Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats.
  • Effects of Ro 40-5967, a new calcium antagonist, and enalapril on cardiac remodeling in renal hypertensive rats.
  • Comparison of the effects of angiotensin II, losartan, and enalapril on baroreflex control of heart rate in conscious rabbits.
  • Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
  • The renin-angiotensin system and volume overload-induced changes in cardiac collagen and elastin.
  • Renal and hormonal responses to repeated treatment with enalapril in non-azotemic cirrhosis with ascites.
  • Action of metoprolol, enalapril, diltiazem, verapamil, and nifedipine on cell growth of vascular smooth muscle cells.
  • Physiological responses to angiotensin II infusion during chronic angiotensin converting enzyme inhibition in dogs on normal, low and high sodium intake.
  • Design, synthesis and enzyme inhibitory activities of new trifluoromethyl-containing inhibitors for angiotensin converting enzyme.
  • Mechanism for hypotensive action of angiotensin converting enzyme inhibitors.
  • Sex influence on renal alpha 2-adrenergic receptor density in the spontaneously hypertensive rat.
  • Chronic effects of SQ29,852, a new angiotensin converting enzyme (ACE) inhibitor with a phosphonic acid group, in experimental hypertensive rats.
  • Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors.
  • Effect of enalapril on left ventricular hypertrophy and left ventricular function in patients with hypertension
  • Altered renal kallikrein and renin gene expression in nephrotic rats and modulation by converting enzyme inhibition.
  • Mediators of the hypotensive response to increased renal perfusion in rabbits.
  • Measurement of angiotensin I converting enzyme inhibition in the heart.
  • Protective effects of enalaprilat against postischemic renal failure.
  • Pharmacological action of (-)-(2S,3aR,7aS)-1-(S)-N-(S)-1-carbonyl-3- phenylpropylalanylhexahydro-2-indolinecarboxylic acid (trandolaprilat) in isolated smooth muscle preparations.
  • Propionyl-L-carnitine limits chronic ventricular dilation after myocardial infarction in rats.
  • Effects of spiraprilat, an angiotensin-converting enzyme inhibitor, on anesthetized dogs in a new model of acute left ventricular failure.
  • Renin-angiotensin system and cell communication in the failing heart.
  • Comparison of the effects of a low-protein diet with the effects of a converting enzyme inhibitor on the progression of renal insufficiency in hypertensive rats.
  • Loin pain-hematuria syndrome associated with thin glomerular basement membrane disease and hemorrhage into renal tubules.
  • Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats.
  • Converting enzyme inhibitors cause pressure-independent resetting of baroreflex control of sympathetic outflow.
  • In vivo inhibition of nitric oxide synthesis does not depend on renin-angiotensin system activation.
  • Regulation of angiotensin II receptor AT1 subtypes in renal afferent arterioles during chronic changes in sodium diet.
  • Comparison of effects of enalapril and captopril on serum potassium concentration in the treatment of malignant hypertension.
  • Effects of enalapril in rats with pressure overload cardiac hypertrophy.
  • Anti-free radical mechanisms in captopril protection against reperfusion injury in isolated rat hearts.
  • Enalaprilat decreases plasma endothelin and atrial natriuretic peptide levels and preload in patients with left ventricular dysfunction after cardiac surgery.
  • Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition.
  • Vasodilator hormonal agents in chronic heart failure: effect of angiotensin-converting enzyme inhibitors
  • Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction.
  • Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure.
  • Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure.
  • Contrasting renal effects of chronic administrations of enalapril and losartan on one-kidney, one clip hypertensive rats.
  • Evaluation of antiarrhythmic activity of captopril and enalaprilat in experimental cardiac arrhythmias in rabbits. Part I.
  • Atrial natriuretic factor and changes in dietary sodium intake in patients with chronic renal failure.
  • Endothelium-dependent effect of perindopril and enalaprilat in rat thoracic aorta.
  • Alteration of neutrophil (PMN) function by heparin, dexamethasone, and enalapril.
  • Collecting duct changes in potassium depletion: effects of ACE inhibition.
  • Changes in cardiac ANG II postmyocardial infarction in rats: effects of nephrectomy and ACE inhibitors.
  • An evaluation of the potential interaction between enalapril and amiloride.
  • N-acetyl-L-cysteine potentiates depressor response to captopril and enalaprilat in SHRs.
  • Are the radical scavenging properties of ACE inhibitors with sulfhydryl groups in therapeutically effective concentrations of quantitative significance?
  • Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry.
  • Influence of age on blood pressure response to enalapril.
  • Enalapril and pressure-diuresis in hypertensive rats transgenic for mouse renin gene.
  • Effects of captopril and enalapril on regional vascular resistance and reactivity in spontaneously hypertensive rats.
  • Splanchnic venous pressure-volume relation during experimental acute ischemic heart failure. Differential effects of hydralazine, enalaprilat, and nitroglycerin.
  • Enalapril cytotoxicity in primary cultures of rat hepatocytes. I. Effects of cytochrome P450 inducers and inhibitors.
  • Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure.
  • Enalapril and myocardial protection from stress by cold
  • Changes of lipid peroxides and antioxidative factors levels in blood of patients treated with ACE inhibitors.
  • Platelet activation and prostacyclin release in essential hypertension.
  • Effect of enalapril on proteinuria after kidney transplantation.
  • Atrial natriuretic peptide ANP(1-98) and ANP(99-126) in patients with severe chronic congestive heart failure: relation to echocardiographic measurements. A subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
  • Radioimmunoassay for the quantitation of lisinopril and enalaprilat.
  • Angiotensin receptor antagonists delay nitric oxide-deficient stroke in stroke-prone rats.
  • Renoprotective effect of enalapril in uninephrectomized spontaneously hypertensive rats with neonatal streptozotocin-induced diabetes.
  • Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha-adrenoceptor blockade, and angiotensin-converting enzyme inhibition.
  • Effect of angiotensin receptor blockade in the rabbit aorta: influence of the endothelium.
  • In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity.
  • Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction.
  • Factors affecting the regional haemodynamic responses to glyceryl trinitrate and molsidomine in conscious rats.
  • Relationship between the regression of left ventricular hypertrophy and the changes in circadian blood pressure after long-term treatment with enalapril in hypertensive patients.
  • Endothelium-dependent relaxations are augmented in rats chronically treated with the angiotensin-converting enzyme inhibitor enalapril.
  • Effects of enalapril on renal parameters in patients with primary glomerulopathies associated with chronic renal failure.
  • Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart.
  • Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
  • Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension.
  • Impact of the renin-angiotensin-aldosterone system on blood pressure response to intravenous enalaprilat in patients with hypertensive crises.
  • The role of the renin-angiotensin system in insulin sensitivity in normotensive subjects.
  • Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart.
  • Contribution of the renin-angiotensin system and of the sympathetic nervous system to blood pressure homeostasis during chronic restriction of sodium intake.
  • The influence of the renin-angiotensin system on adrenergic vasoconstrictor responses in the forearm and splanchnic region in sodium deplete man.
  • Temporal enhancement of renin-aldosterone blockade by enalapril, an angiotensin-converting enzyme inhibitor.
  • Angiotensin II regulates renin gene expression.
  • Diagnosis of unilateral renovascular hypertension: comparative effect of intravenous enalaprilat and oral captopril.
  • Enalapril and the kidney: renal vasodilation and natriuresis due to the inhibition of angiotensin II formation.
  • Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats.
  • Biosensors for the enantioselective analysis of S-enalapril and S-ramipril.
  • Toxicodynamic analysis of cough and inflammatory reactions by angiotensin-converting enzyme inhibitors in guinea pig.
  • Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin II receptor antagonist, and an angiotensin-converting enzyme inhibitor in conscious renovascular hypertensive rats.
  • Suppression of hypotensive responses of captopril and enalapril by the kallikrein inhibitor aprotinin in spontaneously hypertensive rats.
  • Role of aldosterone in the remnant kidney model in the rat.
  • Superficial nephron responses to peritubular capillary infusions of angiotensins I and II.
  • Hemodynamic and humoral responses to enalapril and nifedipine in the rat.
  • Effect of enalapril on restrictive type diastolic filling disorder in severe congestive heart failure
  • Norepinephrine overflow and renin pattern of the individual kidney in patients with unilateral renal artery stenosis.
  • Diabetic nephropathy in the rat: differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor.
  • Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril.
  • Renin mRNA concentration in rat hypothalamus is decreased by enalapril.
  • Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension.
  • In vivo pharmacology of SC-51316, a nonpeptidic angiotensin II receptor antagonist.
  • The effect of enalapril on serum lithium levels in healthy men.
  • Enalapril in treatment of severe heart failure in patients with dilated cardiomyopathy
  • There are no racial, age, sex, or weight differences in the effect of salt on blood pressure in salt-sensitive hypertensive patients.
  • Hemodynamic study of a single oral dose of enalapril in patients with heart failure
  • Cough induced activity of spirapril in rats.
  • Effect of enalapril on body sodium and handling of a sodium chloride load in hypertensive and normotensive rats.
  • Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts.
  • The effect of hyperemia on spinal cord function after temporary thoracic aortic occlusion.
  • Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation.
  • Pharmacologic, metabolic, and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor.
  • Renal afferent arteriolar structure in the genetically hypertensive (GH) rat and the ability of losartan and enalapril to cause structural remodelling.
  • Preservation of renal structure and function in the rat remnant kidney model of chronic renal failure by enalapril treatment.
  • Angiotensin II receptor subtypes in renal cortex of rats and rhesus monkeys.
  • Reduced renal sympathoinhibition in response to acute volume expansion in diabetic rats.
  • Vascular renin-angiotensin system in two-kidney, one clip hypertensive rats.
  • The relationship between systolic blood pressure and microvascular resistance in non-diabetic and diabetic subjects.
  • Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency.
  • Pharmacological evidence that captopril possesses an endothelium-mediated component of vasodilation: effect of sulfhydryl groups on endothelium-derived relaxing factor.
  • Tolerability of long term therapy with enalapril maleate in patients resistant to other therapies and intolerant to captopril.
  • Combined recirculation of the rat liver and kidney: studies with enalapril and enalaprilat.
  • Effect of nifedipine and enalapril on cardiac autonomic activity in elderly hypertensive patients
  • Osteopontin expression in the kidney during unilateral ureteral obstruction.
  • Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation.
  • Effect of enalapril or the thromboxane receptor antagonist, daltroban, in rats with subtotal renal ablation.
  • Role of the endothelium in the vasomotor effects of angiotensin I in isolated arteries with or without inhibition by MK 422.
  • The effect of captopril on the oxidation of plasma lipoproteins.
  • Sex-related differences in the response of spontaneously hypertensive rats to angiotensin-converting enzyme inhibitor.
  • Losartan prevents thromboxane A2/prostanoid (TP) receptor mediated increase in microvascular permeability in the rat.
  • Severe cutaneous reactions to captopril and enalapril; histological study and comparison with early mycosis fungoides.
  • Gender differences in toxicokinetics, liver metabolism, and plasma esterase activity: observations from a chronic (27-week) toxicity study of enalapril/diltiazem combinations in rats.
  • Enalapril hepatotoxicity in the rat. Effects of modulators of cytochrome P450 and glutathione.
  • Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats.
  • The effect of enalapril on the development of diabetic nephropathy in children and adolescents
  • Zinc metabolism in patients treated with captopril versus enalapril.
  • Disposition of enalapril in the perfused rat intestine-liver preparation: absorption, metabolism and first-pass effect.
  • Renal vascular induction of TGF-beta 2 and renin by potassium depletion.
  • Abnormal taurocholate ileal transepithelial transport in atherosclerotic mini-pigs and effects of ACE inhibitors.
  • The use of enalapril in the treatment of feline hypertrophic cardiomyopathy.
  • Necrotizing tracheobronchitis (NTB) following high frequency ventilation: role of an angiotensin converting enzyme inhibitor.
  • Correction of post-renal transplant erythrocytosis by enalapril.
  • Comparison of the transplacental transfer of enalapril, captopril and losartan in sheep.
  • Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
  • Captopril produces endothelium-dependent relaxation of dog isolated renal arteries. Potential role of bradykinin.
  • Effect of enalapril treatment on progression of the nephrotoxic serum nephritis model of renal failure in the rat.
  • Effects of subchronic treatment with trandolapril and enalapril on cardiovascular morphologic alterations in the aged spontaneously hypertensive rat with heart failure.
  • Temporal relationships of treatment with angiotensin converting enzyme inhibitors on the hypertension and cardiac hypertrophy in spontaneously hypertensive rats.
  • Modulation of proximal tubular reabsorption by angiotensin II.
  • Characteristics of renal tubular atrophy in experimental renovascular hypertension: a model of kidney hibernation.
  • Efficacy of different antihypertensive drugs in the emergency department.
  • Evidence for a role for a uterine renin-angiotensin system in decidualization in rats.
  • Role of angiotensin II and vasopressin in cisplatin-induced emesis.
  • Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
  • Enalapril can prevent vascular amplifier development in spontaneously hypertensive rats.
  • Endogenous synthesis of endothelin-1 may mediate a delayed pressor response after injection of endothelin-1 in rats.
  • Increased expression of vascular angiotensin II type 1A receptor gene in glucocorticoid-induced hypertension.
  • Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme.
  • Vasoconstrictor role for vasopressin in conscious, sodium-depleted rats.
  • Regression of left ventricular hypertrophy with 1 year of antihypertensive treatment in type 1 diabetic patients with early nephropathy.
  • Regression of left ventricular hypertrophy in experimental renovascular hypertension: diastolic dysfunction depends more on myocardial collagen than it does on myocardial mass.
  • Evolution of left ventricular hypertrophy and function during long-term treatment of systemic hypertension with enalapril.
  • Reduction of complex ventricular arrhythmias after enalapril treatment in patients with advanced stable heart failure.
  • Effect of enalapril on ventricular remodeling and function during healing after anterior myocardial infarction in the dog.
  • Enalapril: a powerful in vitro non-thiol acantholytic agent.
  • Cardiovascular effects of volatile anesthesia in rabbits: influence of chronic heart failure and enalaprilat treatment.
  • Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism.
  • Effect of ANG II receptor antagonist on albuminuria and renal function in passive Heymann nephritis.
  • Renal vascular effects of antihypertensive therapy in uninephrectomized SHR.
  • Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat.
  • Role of vasopressin in rats with bilateral ureteral obstruction.
  • Effect of chronic treatment with enalapril on glucose tolerance and serum insulin in non-insulin-resistant Japanese patients with essential hypertension.
  • Autoregulation of total and zonal glomerular filtration rate in spontaneously hypertensive rats during antihypertensive therapy.
  • Effect of enalapril on aortic smooth muscle cell polyploidy in the spontaneously hypertensive rat.
  • Enalapril suppresses normal accumulation of elastin and collagen in cardiovascular tissues of growing rats.
  • Enalapril: a well-tolerated and efficacious agent for the pediatric hypertensive patient.
  • Effects of antihypertensive agents on endothelium-dependent and endothelium-independent relaxations.
  • Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension.
  • Interaction of vasopressin, angiotensin and alpha-adrenergic system in sodium depletion in the rat.
  • Enalapril: a well-tolerated and efficacious agent for the paediatric hypertensive patient.
  • Evaluation of the efficacy and safety of monotherapy for significant essential hypertension in adolescents with use of enalapril
  • ACE in three tunicae of rat aorta: expression in smooth muscle and effect of renovascular hypertension.
  • Chronic central administration of enalaprilat lowers blood pressure in stroke-prone spontaneously hypertensive rats.
  • Chronic effects of FR139317 and enalapril on renal failure rats with moderate exercise.
  • Biomolecular changes in the aging myocardium: the effect of enalapril.
  • Dilation of epicardial arteries in conscious dogs induced by angiotensin-converting enzyme inhibition with enalaprilat.
  • Remodelling of resistance arteries by treatment with enalapril in the New Zealand genetically hypertensive rat.
  • Effect of chronic administration of the converting enzyme inhibitor enalapril (MK 421) on brain atrial natriuretic peptide receptors in Wistar-Kyoto and spontaneously hypertensive rats.
  • The angiotensin converting enzyme inhibitor enalapril in acute ischemic renal failure in rats.
  • Stimulation of endothelial autacoid formation by inhibitors of angiotensin-converting enzyme.
  • Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive rat.
  • Characterization of the baroreceptor heart rate reflex during development in spontaneously hypertensive rats.
  • Total body potassium in Bartter's syndrome before and during treatment with enalapril.
  • Renoprotective differences between perindopril and enalapril in the diabetic hypertensive rat do not reflect glomerular angiotensin-converting enzyme activity.
  • Enalapril microbial biosensor.
  • Angiotensin II receptor blockade improves renal function in rats with reduced renal mass.
  • Impact of cyclo-oxygenase blockade on juxtamedullary microvascular responses to angiotensin II in rat kidney.
  • Hemodynamic changes during administration of drugs for mitral regurgitation in dogs.
  • Prophylaxis of experimental bone marrow transplant nephropathy.
  • Blood pressure response to enalaprilic acid in essential hypertension: dose-response and effect of pre-treatment with furosemide.
  • Effects of enalapril on the cardiovascular response to treadmill exercise in patients with mild to moderate systemic hypertension.
  • Analysis of responses to bradykinin: effects of Hoe-140 in the hindquarters vascular bed of the cat.
  • A possible role for the brain renin-angiotensin system in the regulation of LH secretion.
  • Does combined therapy of Ca-channel blocker and angiotensin converting enzyme inhibitor exceed monotherapy in renal protection against hypertensive injury in rats?
  • Effect of a calcium-sensitizing positive inotropic agent MCI-154 and its combined use with enalapril on postischemic contractile dysfunction of dog hearts.
  • Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
  • Diminished glomerular capillary hydraulic conductivity precedes morphologic changes in experimental diabetes mellitus in the rat.
  • Prevention of glomerular capillary hypertension in experimental diabetes mellitus obviates functional and structural glomerular injury.
  • Effects of an alpha-2 adrenoceptor agonist on angiotensin converting enzyme inhibitor-induced hypotension and potentiated allergen-evoked inflammatory skin responses.
  • Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure.
  • Cough associated with captopril and enalapril
  • The angiotensin converting enzyme inhibitors captopril and enalapril inhibit apomorphine-induced oral stereotypy in the rat.
  • Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man.
  • Cough associated with captopril and enalapril.
  • Effects of enalapril and captopril on urinary excretion of kinins and electrolytes in stroke-prone spontaneously hypertensive rats.
  • Neuroendocrine and cardiovascular effects of serotonin: selective role of brain angiotensin on vasopressin.
  • Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study.
  • Role of central catecholaminergic pathways in the actions of endogenous ANG II on sympathetic reflexes.
  • Arterial hypertension caused by low renin: comparison of the calcium antagonist nifedipine and the ACE-inhibitor enalapril as to antihypertensive efficacy
  • Granular juxtaglomerular cells and prorenin synthesis in mice treated with enalapril.
  • Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
  • Effects of enalapril on changes in cardiac output and organ vascular resistances induced by alpha 1- and alpha 2-adrenoceptor agonists in pithed normotensive rats.
  • Cardioprotective effect of enalapril in renovascular and angiotensin II hypertension.
  • Left ventricular filling after long-term angiotensin converting enzyme inhibition in congestive heart failure.
  • Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients.
  • Reduction of albuminuria after angiotensin converting enzyme inhibition in various renal disorders.
  • Enalaprilat, but not cilazaprilat, increases inflammatory skin reactions in guinea-pigs.
  • Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats.
  • Effects of enalapril and clonidine on glomerular structure, function, and atrial natriuretic peptide receptors in SHHF/Mcc-cp rats.
  • Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy.
  • Studies on angiotensin I converting enzyme (ACE) inhibitory effect of imidapril. (I). Inhibition of various tissue ACEs in vitro
  • Kinin antagonist reverses converting enzyme inhibitor-stimulated vascular prostaglandin I2 synthesis.
  • Enalapril maleate affects 2-oxoglutarate metabolism in mitochondria from the rat kidney cortex.
  • Do angiotensin converting enzyme inhibitors lower blood pressure in the rat partly via the humorally mediated antihypertensive system of the renal medulla?
  • Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial infarction.
  • Novel renin inhibitors containing the amino acid statine.
  • Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease.
  • Comparison of renin and converting enzyme inhibition in sodium-deficient dogs.
  • Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms.
  • Effect of angiotensin converting enzyme inhibitor and calcium channel blocker on renal function of spontaneously hypertensive rat
  • Effects of angiotensin converting enzyme inhibition on glomerular number, juxtaglomerular cell activity and renin content in experimental unilateral hydronephrosis.
  • Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm.